Aspirin, caffeine, chlorpheniramine, phenylephrine (Dristan)
Aspirin, caffeine, chlorpheniramine, phenylephrine
Pfizer Laboratories (Pty) Ltd
Registration
- Applicant
- Pfizer Laboratories (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Dristan tablet EACH TABLET CONTAINS ASPIRIN A 325,0 mg CAFFEINE A 16,20 mg CHLORPHENIRAMINE MALEATE A 2,00 mg PHENYLEPHRINE HYDROCHLORIDE A 5,0 mg | Tablet | C0717 | Old Medicine | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Phenylephrine
- when intended for injection
- except ophthalmic preparations containing 0,2 percent or less. (S0)
- except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)
Consolidated Schedules 06 July 2026, lines 7545 to 7552
S3: Caffeine
- when intended for injection.
Consolidated Schedules 06 July 2026, line 3256
S2: Aspirin
- the treatment of children or adolescents; and
- the prophylaxis of cardiovascular disease in adults (S0)
Consolidated Schedules 06 July 2026, lines 1616 to 1620
S2: Chlorpheniramine
Consolidated Schedules 06 July 2026, line 1732
S1: Phenylephrine
- when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent; (S1)
- except ophthalmic preparations containing 0,2 percent or less; (S0)
- except when intended for injection. (S4)
Consolidated Schedules 06 July 2026, lines 1007 to 1014
1 of 10 approved products with this ingredient carry S5 on their leaflet.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.